Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

Research article (Nature Cardiovascular Research, 2023) · cited 13× · AI/ML

academia openalex:W4384206023

Press Enter · cited answer in seconds

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

Summary

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? is a scholarly article^[1].

Key Facts

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?'s instance of is recorded as scholarly article^[2].

⭐ Popularity Graph

0/100 long tail

Quick Facts

Instance of scholarly article

🔗 Connections

Authored by 1

Milton Packer

← Author of 1

Milton Packer

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

[2] ↑ Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? — instance of (P31): scholarly article. wikidata.org.

Class ancestry

[1] ↑ Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? is an instance of scholarly article (scholarly article) [P31, primary]. Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA

4ort.xyz Knowledge Graph. (2026). Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?. Retrieved May 24, 2026, from https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine

MLA

“Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine.

BibTeX

@misc{4ortxyz_dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?}}, year = {2026}, url = {https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine}, note = {Accessed: 2026-05-24}}

LLM prompt

According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? — https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine (retrieved 2026-05-24)

Canonical URL: https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine · Last refreshed: May 24, 2026